A Study Evaluating the Long-Term Safety of ICA-17043 in Sickle Cell Disease Patients With or Without Hydroxyurea Therapy
An Open-Label Extension Study Evaluating the Long-Term Safety of ICA-17043 With or Without Hydroxyurea Therapy in Subjects With Sickle Cell Disease
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Alabama
-
Mobile, Alabama, United States, 36617
- University of South Alabama
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72202
- Arkansas Children's Hospital
-
-
California
-
Oakland, California, United States, 94609
- Children's Hospital Oakland
-
Sacramento, California, United States, 95817
- University of California Davis Medical Center
-
-
Colorado
-
Denver, Colorado, United States, 80262
- University of Colorado Health Sciences Center
-
-
Florida
-
Holly Hill, Florida, United States, 32117
- Century Clinical Research, Inc.
-
Jacksonville, Florida, United States, 32209
- University of Florida Health Science Center
-
-
Georgia
-
Augusta, Georgia, United States, 30912
- Medical College of Georgia
-
Savannah, Georgia, United States, 31404
- Memorial Health University Medical Center
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- University of Illinois Medical Center
-
-
Louisiana
-
Shreveport, Louisiana, United States, 71103
- Sickle Cell Center of Northern Louisiana
-
-
Maryland
-
Baltimore, Maryland, United States, 21205
- Johns Hopkins University School Of Medicine
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Brigham and Women's Hospital
-
-
Michigan
-
Detroit, Michigan, United States, 48201
- Wayne State School of Medicine
-
-
Mississippi
-
Jackson, Mississippi, United States, 39216
- University of Mississippi Medical Center
-
-
New Jersey
-
Hackensack, New Jersey, United States, 07601
- Hackensack University Medical Center
-
New Brunswick, New Jersey, United States, 08903
- Robert Wood Johnson Medical Center
-
Newark, New Jersey, United States, 07112-2027
- Newark Beth Israel Medical Center
-
-
New York
-
Brooklyn, New York, United States, 11203
- SUNY Downstate Medical Center
-
Brooklyn, New York, United States, 11215
- New York Methodist Hospital
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27514
- University of North Carolina Hospitals
-
Durham, North Carolina, United States, 27710
- Duke University Medical Center
-
Greenville, North Carolina, United States, 27858
- East Carolina University School of Medicine
-
Winston-Salem, North Carolina, United States, 27157
- Wake Forest University School of Medicine
-
-
Ohio
-
Cincinnati, Ohio, United States, 45219
- University of Cincinnati
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19107
- Thomas Jefferson University Hospital
-
Philadelphia, Pennsylvania, United States, 19134-1095
- St. Christopher's Hospital for Children
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Medical University of South Carolina
-
-
Texas
-
Houston, Texas, United States, 77030
- Baylor College of Medicine
-
-
Virginia
-
Richmond, Virginia, United States, 23298
- Virginia Commonwealth University
-
Richmond, Virginia, United States, 23298-0157
- Medical College of Virginia
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Successfully completed Study ICA-17043-10
- Discontinued Study 10 or 12 following the DMC recommendations because he/she was not on HU, and has since been on a stable dose of HU for at least 3 months prior to Day 1
- Male, or female not capable of becoming pregnant or using appropriate birth control
- Has willingly given written informed consent to participate in this study
Exclusion Criteria:
- The subject, if female, has a positive urine pregnancy test on Day 1 (before entering study)
- The subject is presently unsuitable for participation in this long-term study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Safety measures only
Time Frame: at least 60 weeks
|
at least 60 weeks
|
|
No efficacy outcome measures
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Director: Jonathan W Stocker, PhD, Icagen
Study record dates
Study Major Dates
Study Start
Study Start
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- ICA-17043-12
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.